Document is current
Any future updates will be listed below
-
Authors
Shulman, Melanie https://orcid.org/0009-0002-5550-9077
Wu, Shuang
Ziogas, Nick
Edwards, Amanda
Collins, Jessica
Lin, Lin
Tien, Irene
Curiale, Gioacchino
Li, Yumeng
Mummery, Catherine https://orcid.org/0000-0002-6739-0803
Lane, Roger
Junge, Candice
Beaver, John
Tian, Ying
Landen, Jaren
Bullain, Szofia
Gallagher, Diana
-
Funding
Funding for this research was provided by:
Ionis and Biogen Inc.
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 31 October 2025
First Online: 11 February 2026
Competing interests
: M.S., S.W., A.E., J.C., G.C., S.B. and D.G. are employees of and may hold stock in Biogen, Inc. N.Z., L.L., I.T., Y.L., J.B., Y.T. and J.L. are former employees of and may hold stock in Biogen, Inc. R.L. and C.J. are employees of Ionis Pharmaceuticals and may hold stock. C.M. is a BIIB080 trial site investigator and is supported by the National Institute for Health and Care Research Biomedical Research Centre at University College London Hospitals and has acted as a consultant to Biogen, Roche, Eli Lilly, Prevail, Alnylam, Alector, Eisai, WAVE, PeerView and Ionis Pharmaceuticals.
